Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Regeneron Pharmaceuticals REGN Faces Securities Class Action After Losing 9 Billion Value Following Q3 2024 Earnings Report Hagens Berman

January 09, 2025
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is facing a securities class action after losing $9 billion in value following its Q3 2024 earnings report. The law firm Hagens Berman announced that it is investigating potential securities fraud claims on behalf of Regeneron shareholders. The investigation focuses on whether the company made false or misleading statements to investors regarding its financial performance. Shareholders who purchased Regeneron stocks between July 1, 2024, and October 27, 2024, are encouraged to contact Hagens Berman for more information on their rights and potential remedies. It is essential for investors to seek professional advice, such as Stocks Prognosis, to make informed decisions about the future movement of Regeneron Pharmaceuticals' stocks.
If you want to leave a comment, then you need Login or Register





Other data for REGN

Related data

REGNSeptember 5, 2025Regeneron Pharmaceuticals Inc. Continues to Impress Investors with Strong Performance  ~1 min.

Regeneron Pharmaceuticals Inc. (REGN) has been making waves in the stock market recently, with Evercore ISI maintaining a buy rating and a price target of 750....


REGNJuly 5, 2025Regeneron Pharmaceuticals: Revolutionizing Healthcare with Innovative Drug Approvals  ~1 min.

Regeneron Pharmaceuticals, Inc. recently made headlines with the approval of Dupixent by the US FDA, in collaboration with Sanofi....


REGNJune 27, 2025Regeneron Pharmaceuticals Inc. Continues to Impress Investors as UBS Lowers Price Target  ~1 min.

Regeneron Pharmaceuticals Inc. has been making waves in the biotech industry, with impressive financial and operating results....


REGNJune 5, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 33.76% Profit Margin  ~1 min.

QuantWave's forecast signal for REGENERON PHARMACEUTICALS, INC. on December 13, 2024, predicted a short direction with a price of 728.18 $. On June 5, 2025, the stock reached the target price of 482....


REGNJune 5, 2025REGENERON PHARMACEUTICALS, INC. Hits Forecast Price Target with a 32.0% Profit  ~1 min.

REGENERON PHARMACEUTICALS, INC. has successfully reached the forecast price target set by QuantWave, resulting in a profit of 32.0%. The forecast signal was issued on December 31, 2024, with a price of $709....


REGNJune 4, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave Price Target Forecast with 27.18% Profit  ~2 min.

REGENERON PHARMACEUTICALS, INC. (REGN) has successfully reached the price target forecast set by QuantWave, resulting in a profit of 27.18%....


REGNJune 4, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with Profit of 26.25%  ~1 min.

REGENERON PHARMACEUTICALS, INC. stock recently achieved the price target forecast set by QuantWave on March 21, 2025. The forecast indicated a short direction, with the stock price at $657....


REGNJune 4, 2025REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with 26.25% Profit: QuantWave's Success in Stock Prediction  ~2 min.

REGENERON PHARMACEUTICALS, INC. has recently reached the price target forecast set by QuantWave on June 4, 2025....


REGNJune 4, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave Price Target Forecast with 27.18% Profit  ~1 min.

REGENERON PHARMACEUTICALS, INC. (ticker: REGN) has successfully achieved the price target forecast set by QuantWave, realizing a profit of 27.18%....


REGNMay 30, 2025REGENERON PHARMACEUTICALS, INC. Hits QuantWave's Price Target with 20.42% Profit  ~2 min.

In a recent success story for QuantWave, the automated forecasting platform accurately predicted a short position for REGENERON PHARMACEUTICALS, INC....


REGNJanuary 4, 2025Regeneron Pharmaceuticals Inc.: A Strong Investment Opportunity for Shareholders  ~1 min.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) has proven to be a successful investment option for shareholders, with a decent 89% return over the last five years....


REGNJanuary 6, 2025Regeneron Pharmaceuticals Inc. Continues to Impress Investors with Strong Financial Performance  ~1 min.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) has reported a remarkable 89% return for its investors over the last five years, according to a recent report by Yahoo Finance....


REGNJanuary 12, 2025Regeneron Pharmaceuticals Faces Shareholder Class Action Lawsuit  ~1 min.

Regeneron Pharmaceuticals, Inc., a leading biotechnology company, is currently facing a shareholder class action lawsuit....


REGNJanuary 2, 2025Regeneron Pharmaceuticals: An Impressive 89% Return Over the Last Five Years  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been a rewarding investment for shareholders, with a solid 89% return over the past five years, according to Yahoo Finance....


REGNJanuary 2, 2025Regeneron Pharmaceuticals Continues to Impress Investors with Strong Returns  ~1 min.

In the past five years, Regeneron Pharmaceuticals (NASDAQ:REGN) has delivered a solid return of 89%, making it a favorable choice for investors....